uniQure N.V.

QURE Healthcare Biotechnology

uniQure N.V.’s revenue for fiscal 2025 (year ended December 2025) was $16.1 million, down 40.6% from fiscal 2024. In the quarter to June 2026, revenue grew 11.0%, EPS fell 76.8%, free cash flow grew 27.7% and total debt fell 3.27%, each against the same quarter a year earlier.

21.72 0.80 −3.55%
Market cap
$1.6B
P/E
0.0×
Fwd P/E
−7.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.80
Beneish M
−2.95
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
Piotroski F-Score
5 4 5 4

+8 more TTM periods

ROE
(157.61%) (228.24%) (207.10%) (165.27%)
ROA
(32.13%) (30.18%) (28.81%) (30.65%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(33.09%) (36.74%) (32.79%) (37.27%)
Average Days of Receivables
112.95 71.86 132.94 89.98
Free Cash Flow per Share
(2.44) (2.75) (3.10) (2.62)
Free Cash Flow
(161.45) (172.56) (178.40) (153.60)
Capital Expenditures
(0.66) (0.45) (0.44) (0.36)
Other line items
Cash ROIC
(13.63%) (21.96%) (20.48%) (15.76%)
Accounts Receivable Turnover
3.28 5.95 2.74 3.42
Accounts Payable Turnover
0.27 0.35 0.27 0.32
Inventory Turnover
0.00 0.00 0.00 0.00
Average Days of Payables
1,296.24 940.07 1,119.25 1,215.63
Days of Inventory on Hand
0.00 0.00 0.00 0.00
Tax Rate
0.03 0.03 0.03 0.05
Research and Development Expense of Revenue
708.49% 739.01% 873.85% 918.86%
Selling, General and Administrative Expense of Revenue
420.32% 412.40% 406.61% 350.61%
Share Based Compensation of Revenue
97.96% 101.47% 109.82% 112.79%
Interest Coverage
(3.35) (3.15) (2.99) (2.89)
Operating CF/Net income
0.64 0.82 0.89 0.65
Depreciation/Fixed assets
1.27 1.10 1.07 1.05
Capex/Depreciation
(0.05) (0.03) (0.03) (0.02)
Revenue per Share
0.28 0.29 0.28 0.27
Operating CF per Share
(2.43) (2.74) (3.09) (2.62)
Capex per Share
(0.01) (0.01) (0.01) (0.01)
Capex to Sales
0.04 0.03 0.03 0.02

Fold the line items

Columns are period end dates